277 related articles for article (PubMed ID: 27074519)
1. Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis.
Suthoff ED; Bonafede M; Limone B; O'Callaghan L; Sawicki GS; Wagener JS
J Med Econ; 2016 Sep; 19(9):845-51. PubMed ID: 27074519
[TBL] [Abstract][Full Text] [Related]
2. Adherence to lumacaftor-ivacaftor therapy in patients with cystic fibrosis in France.
Olivereau L; Nave V; Garcia S; Perceval M; Rabilloud M; Durieu I; Reynaud Q
J Cyst Fibros; 2020 May; 19(3):402-406. PubMed ID: 31902692
[TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
[TBL] [Abstract][Full Text] [Related]
4. Effect of Lumacaftor/Ivacaftor on Pulmonary Exacerbation Rates in Members with Cystic Fibrosis in a Medicaid Population.
Tesell MA; Alper CJ; Bacon R; Greenwood BC; Lenz K; Jeffrey PL; Stevens K
J Manag Care Spec Pharm; 2019 Sep; 25(9):1021-1025. PubMed ID: 31456498
[TBL] [Abstract][Full Text] [Related]
5. Effectivenesss of ivacaftor in severe cystic fibrosis patients and non-G551D gating mutations.
Salvatore D; Carnovale V; Iacotucci P; Braggion C; Castellani C; Cimino G; Colangelo C; Francalanci M; Leonetti G; Lucidi V; Manca A; Vitullo P; Ferrara N
Pediatr Pulmonol; 2019 Sep; 54(9):1398-1403. PubMed ID: 31237430
[TBL] [Abstract][Full Text] [Related]
6. Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experience.
Dagan A; Cohen-Cymberknoh M; Shteinberg M; Levine H; Vilozni D; Bezalel Y; Bar Aluma BE; Sarouk I; Ashkenazi M; Lavie M; Tsabari R; Blau H; Kerem E; Bentur L; Efrati O; Livnat G
Respir Med; 2017 Oct; 131():225-228. PubMed ID: 28947035
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Ivacaftor Therapy for Treatment of Cystic Fibrosis Patients With the G551D Gating Mutation.
Wherry K; Williamson I; Chapman RH; Kuntz KM
Value Health; 2020 Oct; 23(10):1332-1339. PubMed ID: 33032777
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal effects of ivacaftor and medicine possession ratio in people with the
Mitchell RM; Jones AM; Stocking K; Foden P; Barry PJ
Thorax; 2021 Sep; 76(9):874-879. PubMed ID: 33579778
[TBL] [Abstract][Full Text] [Related]
9. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
10. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
Guerra L; D'Oria S; Favia M; Castellani S; Santostasi T; Polizzi AM; Mariggiò MA; Gallo C; Casavola V; Montemurro P; Leonetti G; Manca A; Conese M
Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004
[TBL] [Abstract][Full Text] [Related]
11. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation.
Trimble AT; Donaldson SH
J Cyst Fibros; 2018 Mar; 17(2):e13-e16. PubMed ID: 29079142
[TBL] [Abstract][Full Text] [Related]
12. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.
Heltshe SL; Mayer-Hamblett N; Burns JL; Khan U; Baines A; Ramsey BW; Rowe SM;
Clin Infect Dis; 2015 Mar; 60(5):703-12. PubMed ID: 25425629
[TBL] [Abstract][Full Text] [Related]
13. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor.
Jennings MT; Dezube R; Paranjape S; West NE; Hong G; Braun A; Grant J; Merlo CA; Lechtzin N
Ann Am Thorac Soc; 2017 Nov; 14(11):1662-1666. PubMed ID: 28406713
[TBL] [Abstract][Full Text] [Related]
14. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor.
Bessonova L; Volkova N; Higgins M; Bengtsson L; Tian S; Simard C; Konstan MW; Sawicki GS; Sewall A; Nyangoma S; Elbert A; Marshall BC; Bilton D
Thorax; 2018 Aug; 73(8):731-740. PubMed ID: 29748252
[TBL] [Abstract][Full Text] [Related]
15. Ivacaftor for cystic fibrosis: An evaluation of real world utilisation and expenditure in the Irish Healthcare Setting.
Corcoran A; Hickey N; Barry M; Usher C; McCullagh LM
Ir Med J; 2017 Aug; 110(7):619. PubMed ID: 29169001
[TBL] [Abstract][Full Text] [Related]
16. A safety evaluation of ivacaftor for the treatment of cystic fibrosis.
McColley SA
Expert Opin Drug Saf; 2016 May; 15(5):709-15. PubMed ID: 26968005
[TBL] [Abstract][Full Text] [Related]
17. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
Davies JC; Cunningham S; Harris WT; Lapey A; Regelmann WE; Sawicki GS; Southern KW; Robertson S; Green Y; Cooke J; Rosenfeld M;
Lancet Respir Med; 2016 Feb; 4(2):107-15. PubMed ID: 26803277
[TBL] [Abstract][Full Text] [Related]
18. The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review.
Dryden C; Wilkinson J; Young D; Brooker RJ;
Arch Dis Child; 2018 Jan; 103(1):68-70. PubMed ID: 27288428
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland.
Kirwan L; Fletcher G; Harrington M; Jeleniewska P; Zhou S; Casserly B; Gallagher CG; Greally P; Gunaratnam C; Herzig M; Linnane B; McElvaney NG; McKone EF; McNally P; Mullane D; Ní Chróinín M; O'Mahony M; Plant BJ; Jackson AD
Ann Am Thorac Soc; 2019 Feb; 16(2):209-216. PubMed ID: 30427731
[TBL] [Abstract][Full Text] [Related]
20. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.
Talamo Guevara M; McColley SA
Expert Opin Drug Saf; 2017 Nov; 16(11):1305-1311. PubMed ID: 28846049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]